US 10-Year Treasury Yield at 6% Emerges as New Market Risk Threshold 
Japan Private-Sector Growth Slows as Domestic Demand Weakens 
Russian Envoy Dmitriev Heads to US for Ukraine Talks 
China’s ‘Lipstick King’ Says AI Won’t Replace Livestream Hosts 
Asian Stocks Fall as Bond Yields Surge Ahead of Trump-Xi Summit 
Asian Currencies Muted as Dollar Firms Ahead of Trump-Xi Summit 
Australia Unemployment Hits Five-Year High Despite Strong Jobs Growth 
Oil Prices Rise as U.S.-Iran Talks Fuel Diplomacy Hopes 
RBA Says ASX Still Falls Short on Governance and Risk Controls 
US Dollar Hits Two-Month High as Fed Rate Hike Bets Rise 
European Stocks Slip as Iran Tensions Offset Strong Eurozone Data 
Gold Prices Rise as Oil Slump Eases Fed Rate Hike Fears 
Asian Stocks Mixed Ahead of Trump-Xi Meeting 
Mexico-US Trade Talks Delayed to October as Tariff Negotiations Continue 
Gold Drops Over 1% as Dollar, Treasury Yields Surge on Fed Rate Hike Bets 
Oil Prices Surge as U.S.-Iran Diplomacy Hopes Fade 
Add as a preferred source on Google
Swiss pharmaceutical leader Roche confirmed it has no plans for layoffs, emphasizing a healthy business outlook. CEO Thomas Schinecker highlighted steady research funding and workforce stability despite global economic challenges in Europe and China, as well as setbacks in cancer drug development.
Roche Maintains Workforce Stability Amid Market Challenges
Roche, a Swiss pharmaceutical corporation, does not intend to reduce its workforce, and the company's business is doing well. According to a statement made by CEO Thomas Schinecker, which was published in a Swiss publication on Sunday, Investing.com shares.
The stock price of Roche has dropped significantly below the highs it reached in April 2022, and the CEO was questioned about the company's plans for personnel in light of recent setbacks in the company's efforts to produce pharmaceuticals to cure a variety of illnesses, including cancer.
Schinecker responded to a question about whether or not the company was preparing to lay off employees by saying, "The number of workers is constant to slightly increasing," during an interview with the NZZ am Sonntag.
Research and Development Budgets Remain Steady
"I can say with certainty that we have a very healthy business. And we don't have a growth problem either," he remarked, pointing out that Roche's funding for research and development was consistent and not expanding. He also included this information in his statement.
When Schinecker was asked when Roche's intended anti-obesity medicine would be available for purchase, he responded that it may be as early as 2029 or perhaps earlier.
European Economic Struggles Create Headwinds for Recovery
While discussing the forecast for the coming year in a broader sense, particularly in light of the recent difficulties that the German economy has been experiencing, the CEO of Roche stated that Europe still faced problems.
"There's some economic growth in the United States, but things are more difficult in China at the moment," he explained to reporters. "And in Europe it will take some time before we get out of this."
